Published in Br J Cancer on August 01, 2006
ERbeta in breast cancer--onlooker, passive player, or active protector? Steroids (2008) 1.42
ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta (2009) 1.41
Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer (2010) 1.26
Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther (2015) 1.14
Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol (2009) 1.13
CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells. Cancer Res (2011) 1.06
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res (2011) 1.05
Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas. Breast Cancer Res Treat (2008) 1.03
Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators. Mol Syst Biol (2013) 1.03
Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer. Proc Natl Acad Sci U S A (2014) 0.97
Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch (2009) 0.96
Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers. Histopathology (2008) 0.93
Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma. J Cancer Res Clin Oncol (2013) 0.91
Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody. J Cell Biochem (2012) 0.90
Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients. Breast Cancer Res (2009) 0.88
Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells. Mol Endocrinol (2013) 0.86
Sex hormone receptor repertoire in breast cancer. Int J Breast Cancer (2013) 0.86
Estrogen receptor-beta and breast cancer: translating biology into clinical practice. Steroids (2012) 0.84
Claudin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer (2013) 0.84
ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer. BMC Cancer (2014) 0.84
PKCα and ERβ Are Associated with Triple-Negative Breast Cancers in African American and Caucasian Patients. Int J Breast Cancer (2012) 0.83
The evolving role of oestrogen receptor beta in clinical breast cancer. Breast Cancer Res (2008) 0.83
Estrogen receptor beta impacts hormone-induced alternative mRNA splicing in breast cancer cells. BMC Genomics (2015) 0.82
Serum estrogen receptor bioactivity and breast cancer risk among postmenopausal women. Endocr Relat Cancer (2014) 0.80
Lack of functional TSLP receptors mitigates Th2 polarization and the establishment and growth of 4T1 primary breast tumours but has different effects on tumour quantities in the lung and brain. Scand J Immunol (2013) 0.80
Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors. J Cancer Res Clin Oncol (2013) 0.80
Association of TRPS1 gene with different EMT markers in ERα-positive and ERα-negative breast cancer. Diagn Pathol (2014) 0.80
Prognostic significance of full-length estrogen receptor beta expression in stage I-III triple negative breast cancer. Am J Transl Res (2015) 0.79
Gender effect in experimental models of human medulloblastoma: does the estrogen receptor β signaling play a role? PLoS One (2014) 0.79
Estrogen receptor β2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions. J Cancer Res Clin Oncol (2014) 0.77
The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo. Breast Cancer Res (2014) 0.76
Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. Clin Breast Cancer (2016) 0.75
Tumor suppressor p53 and estrogen receptors in nuclear-mitochondrial communication. Mitochondrion (2013) 0.75
Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ. Oncotarget (2016) 0.75
Identification of Claudin 1 Transcript Variants in Human Invasive Breast Cancer. PLoS One (2016) 0.75
The effect of antineoplastic drugs in a male spontaneous mammary tumor model. PLoS One (2013) 0.75
Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer. Cancer Biol Ther (2014) 0.75
Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int (2015) 0.75
ERα and ERβ co-expression: An indicator of aggressive tumors and hormonal sensitivity. Oncol Lett (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48
Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science (1997) 6.60
High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer (2005) 3.07
Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res (2004) 2.67
Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A (2004) 2.64
Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat (1998) 2.42
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res (2004) 2.38
NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A (2004) 2.33
Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol (2001) 2.21
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res (2001) 2.21
ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology (2001) 2.18
Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol (2002) 2.13
Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol (2000) 2.07
Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest (2002) 2.06
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res (2003) 2.01
Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc Natl Acad Sci U S A (2000) 1.97
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker? Cancer (2003) 1.88
Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res (1998) 1.85
The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia (1998) 1.75
A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev (2005) 1.74
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol (2001) 1.71
Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res (2002) 1.71
Selective loss of estrogen receptor beta in malignant human colon. Cancer Res (2000) 1.63
Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci U S A (2002) 1.63
Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A (2001) 1.55
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res (2004) 1.54
Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res (1998) 1.46
Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett (2004) 1.45
Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol (2003) 1.43
Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer (1994) 1.40
Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol (2002) 1.34
Estrogen receptor beta expression in invasive breast cancer. Hum Pathol (2001) 1.30
Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab (2004) 1.29
Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res (1999) 1.28
Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br J Cancer (2004) 1.28
Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc Natl Acad Sci U S A (1999) 1.26
Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res (2004) 1.25
Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res (1999) 1.23
Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett (2001) 1.19
The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol (2004) 1.18
Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol (2003) 1.17
ERbeta1 and the ERbeta2 splice variant (ERbetacx/beta2) are expressed in distinct cell populations in the adult human testis. J Clin Endocrinol Metab (2002) 1.14
ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene (2004) 1.12
Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer (2002) 1.08
Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer (2004) 1.07
Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res (2002) 1.06
The NCIC-Manitoba Breast Tumor Bank: a resource for applied cancer research. CMAJ (1996) 1.05
Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta. J Endocrinol (2002) 1.05
Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol (2005) 1.04
Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin Cancer Res (2005) 1.04
Apoptosis in breast cancer: relationship with other pathological parameters. Endocr Relat Cancer (1999) 1.02
Estrogen receptor-beta mRNA variants in human and murine tissues. Mol Cell Endocrinol (1998) 1.02
Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer. The Quicgel method. Am J Clin Pathol (1999) 1.01
Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer (2002) 1.00
Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer (2006) 0.98
The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res (2004) 0.97
Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res (2002) 0.95
Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol (2003) 0.88
Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol (2003) 0.86
Analysis of the potential contribution of estrogen receptor (ER) beta in ER cytosolic assay of breast cancer. Int J Cancer (2001) 0.86
New insights into estrogen receptor function in human breast cancer. Ann Med (2003) 0.85
Expression of estrogen receptor variant messenger RNAs and determination of estrogen receptor status in human breast cancer. Am J Pathol (1997) 0.85
ERbeta sensitizes breast cancer cells to retinoic acid: evidence of transcriptional crosstalk. Mol Cancer Res (2004) 0.84
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol (2001) 2.71
The steroid receptor RNA activator is the first functional RNA encoding a protein. FEBS Lett (2004) 1.92
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol (2001) 1.71
Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet (2001) 1.66
Eosinophilic fasciitis in a pair of siblings. Arthritis Rheum (1989) 1.66
Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol (1999) 1.56
Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res (1998) 1.46
Pro-protein convertase gene expression in human breast cancer. Int J Cancer (1997) 1.43
Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res (2000) 1.42
The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res (1998) 1.41
Microdissection RT-PCR analysis of gene expression in pathologically defined frozen tissue sections. Biotechniques (1996) 1.39
Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Cancer Res (1985) 1.37
The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin Cancer Res (1999) 1.37
Level of ubiquitinated histone H2B in chromatin is coupled to ongoing transcription. Biochemistry (1990) 1.37
Estrogen induces insulin-like growth factor-I expression in the rat uterus. Mol Endocrinol (1987) 1.36
Beware of connective tissue proteins: assignment and implications of collagen absorptions in infrared spectra of human tissues. Biochim Biophys Acta (1995) 1.34
Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab (1997) 1.34
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res (2001) 1.34
Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res (1999) 1.34
Expression of lumican in human breast carcinoma. Cancer Res (1998) 1.33
Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer (2012) 1.33
Expression of the steroid receptor RNA activator in human breast tumors. Cancer Res (1999) 1.32
Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma. Cancer Res (1996) 1.31
High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature (1980) 1.29
International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group. Eur J Pediatr (1998) 1.24
Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res (1999) 1.23
Lumican and decorin are differentially expressed in human breast carcinoma. J Pathol (2000) 1.21
Psoriasin (S100A7). Int J Biochem Cell Biol (1998) 1.20
Characterization of estrogen receptor variant mRNAs from human breast cancers. Mol Endocrinol (1992) 1.18
Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol (2003) 1.17
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer (2002) 1.16
A new human breast carcinoma cell line (PMC42) with stem cell characteristics. III. Hormone receptor status and responsiveness. J Natl Cancer Inst (1984) 1.14
Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and nm23. Cancer Res (2001) 1.14
S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer. Oncogene (2010) 1.09
Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. Oncogene (2008) 1.05
Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol (2005) 1.04
A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (1997) 1.04
Inhibition of transcription selectively reduces the level of ubiquitinated histone H2B in chromatin. Biochem Biophys Res Commun (1994) 1.04
Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro. Cancer Res (1983) 1.02
Estrogen receptor-beta mRNA variants in human and murine tissues. Mol Cell Endocrinol (1998) 1.02
Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer (2002) 1.00
Evidence for a ras gene mutation in azoxymethane-induced colonic aberrant crypts in Sprague-Dawley rats: earliest recognizable precursor lesions of experimental colon cancer. Carcinogenesis (1992) 0.99
Estrogen receptor variants in normal human mammary tissue. J Natl Cancer Inst (1996) 0.99
Mechanisms of oestrogen antagonism by nonsteroidal antioestrogens. Mol Cell Endocrinol (1982) 0.99
Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen. Cancer Res (1984) 0.96
Potential role of estrogen receptor alpha (ERalpha) phosphorylated at Serine118 in human breast cancer in vivo. J Steroid Biochem Mol Biol (2006) 0.96
Microsomal binding sites for nonsteroidal anti-estrogens in MCF 7 human mammary carcinoma cells. Demonstration of high affinity and narrow specificity for basic ether derivatives of triphenylethylene. J Biol Chem (1984) 0.96
Estrogen receptor variants and mutations. J Steroid Biochem Mol Biol (1997) 0.95
Measurement of the relative binding affinity of zearalenone, alpha-zearalenol and beta-zearalenol for uterine and oviduct estrogen receptors in swine, rats and chickens: an indicator of estrogenic potencies. Comp Biochem Physiol C (1989) 0.94
Role of wild-type estrogen receptor-beta in mitochondrial cytoprotection of cultured normal male and female human lens epithelial cells. Am J Physiol Endocrinol Metab (2008) 0.94
Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers. Histopathology (2008) 0.93
Mammaglobin, a potential marker of breast cancer nodal metastasis. J Pathol (1999) 0.93
The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis. Br J Cancer (1999) 0.91
Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol (1996) 0.90
Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans. J Clin Endocrinol Metab (1999) 0.90
Progestin regulation of epidermal growth factor receptor in human mammary carcinoma cells. Cancer Res (1986) 0.90
Preimplantation development of in vitro-matured and in vitro-fertilized ovine zygotes: comparison between coculture on oviduct epithelial cell monolayers and culture under low oxygen atmosphere. Biol Reprod (1994) 0.89
c-myc oncogene expression in estrogen-dependent and -independent breast cancer. Clin Chem (1993) 0.88
The binding of tamoxifen to human mammary carcinoma cytosol. Eur J Cancer (1980) 0.88
Oestrogen receptor variants and mutations in human breast cancer. Ann Med (1997) 0.88
Antitumor activity of clomiphene analogs in vitro: relationship to affinity for the estrogen receptor and another high affinity antiestrogen-binding site. J Clin Endocrinol Metab (1983) 0.88
Production of digoxigenin-labelled RNA probes and the detection of cytokine mRNA in rat spleen and brain by in situ hybridization. Brain Res Brain Res Protoc (1998) 0.88
Identification of differentially expressed genes using minute amounts of RNA. Biotechniques (1996) 0.87
Biological actions of prolactin in human breast cancer. Recent Prog Horm Res (1987) 0.87
Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration. Cancer Res (1984) 0.87
Estrogen induction of N-myc and c-myc proto-oncogene expression in the rat uterus. Endocrinology (1987) 0.87
Identification of a serum-inducible messenger RNA (5B10) as the mouse homologue of calcyclin: tissue distribution and expression in metastatic, ras-transformed NIH 3T3 cells. Cell Growth Differ (1990) 0.87
Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res (1998) 0.87
Human small breast epithelial mucin: the promise of a new breast tumor biomarker. DNA Cell Biol (2004) 0.86
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. J Biol Chem (2000) 0.86
Estrogen regulates the association of intermediate filament proteins with nuclear DNA in human breast cancer cells. J Biol Chem (1998) 0.86